Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study

Archives of Internal Medicine

Volumn 162, Issue 18, 2002, Pages 2113-2123

  Pavelká, Karel ^a,b   Gatterová, Jindriska ^b   Olejarová, Marta ^b   Machacek, Stanislav ^b   Giacovelli, Giampaolo ^c   Rovati, Lucio C ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^c Rotta Research Laboratorium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE SULFATE; PARACETAMOL; PLACEBO; VIARTRIL S; XICIL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLECYSTITIS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPEPSIA; ECZEMA; FEMALE; FUNCTIONAL ASSESSMENT; HIP FRACTURE; HUMAN; KNEE ARTHRITIS; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME; WALKING;

ADMINISTRATION, ORAL; AGED; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE; HUMANS; KNEE JOINT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; TREATMENT OUTCOME;

EID: 0037078298     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.18.2113     Document Type: Article

References (59)

1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41:1343-1355.
2. Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum. 1995;38:1134-1141.
3. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59:936-944.
4. Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994;84:351-358.
5. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights, part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635-646.
6. Felson DT, Lawrence RC, Hochberg MC, et al. Osteoarthritis: new insights, part 2: treatment approaches. Ann Intern Med. 2000;133:726-737.
7. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905-1915.
8. Rashad S, Revell P, Hemmingway A, Low F, Rainsford K, Walker F. Effect of nonsteroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989; 2:519-522.
9. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307-314.
10. Van Kuijk C, Cheng X, Hottya G, et al. The effects of rofecoxib and diclofenac on knee osteoarthritis articular cartilage: the results from one-year prospective clinical trials [abstract]. Arthritis Rheum, 2000;43(suppl):924.
11. Hamerman D. The biology of osteoarthritis. N Engl J Med. 1989;320:1322-1330.
12. McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283:1469-1475.
13. Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy fortreating osteoarthritis [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001;issue 2.
14. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251-256.
15. McAlindon T. Glucosamine for osteoarthritis: dawn of a new era? Lancet. 2001; 357:247-248.
16. Chard J, Dieppe P. Glucosamine for osteoarthritis: magic, hype or confusion? BMJ. 2001;322:1439-1440.
17. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039-1049.
18. Kellgren JK, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis. 1957;16:494-501.
19. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee: validation-value in comparison with other assessment tests. Scand J Rheumatol. 1987;65(suppl):85-89.
20. Dougados M, for the Group for the Respect of Ethics and Excellence in Science. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis. 1996;55:552-557.
21. Altman R, Brandt K, Hochberg M, Moskowitz R. Design and conduct of clinical trials of patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage. 1996;4:217-243.
22. Pavelká K, Gatterová J, Gollerova V, Urbanova Z, Sedlackova M, Altman RD. A 5-year randomised controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000;8:335-342.
23. Lequesne M. Quantitative measurements of joint space width during progression of osteoarthritis: chondrometry. In: Kuetter KE, Goldberg VM, eds. Osteoarthritic Disorders. Rosemont, III: American Academy of Orthopaedic Surgeons; 1995:427-444.
24. Altman RD, Hochberg M, Murphy WA, Wolfe F, Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995;3(suppl A): 3-70.
25. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
26. Lequesne M, Brandt K, Bellamy N, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol. 1994;21:65-73.
27. Hollis S, Campbell F. What is meant by intention to treat analysis? survey of published randomised controlled trials. BMJ. 1999;319:670-674.
28. Herxenberg LA, Moore WA, De Rosa SC. Estimation of missing values [letter]. Lancet. 1999;354:686.
29. Ravaud P, Girardeau B, Auleley GR, et al. Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis. 1998;57:624-629.
30. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
31. Matthews JSN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230-235.
32. Committee for Proprietary Medicinal Products. Points to Consider on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis. London, England: The European Agency for the Evaluation of Medicinal Products; 1998.
33. Center for Drug Evaluation and Research. Clinical Development Programs for Drugs, Devices and Biological Products Intended for the Treatment of Osteoarthritis. Rockville, Md: US Food and Drug Administration; 1999.
34. Lethbridge-Cejku M, Hochberg MC, Scott WW Jr, Plato CC, Tobin JD. Longitudinal change in joint space of the knee: data from the Baltimore Longitudinal Study of Aging [abstract]. Arthritis Rheum. 1995;38(suppl):S262.
35. Neuhauser KB, Anderson JJ, Felson DT. Rate of joint space narrowing in normal knees and knees with osteoarthritis [abstract]. Arthritis Rheum. 1994;37(suppl): S423.
36. Dieppe PA, Cushnaghan J, Shepstone L. The Bristol "OA500" Study: progression of osteoarthritis (OA) over 3 years and the relationship between clinical and radiographic changes at the knee joint. Osteoarthritis Cartilage. 1997;5:87-97.
37. Mazzucca SA, Brandt KD, Katz BP. Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis? Osteoarthritis Cartilage. 1997;5:217-226.
38. Ravaud P, Ayral X, Dougados M. Radiologic progression of hip and knee osteoarthritis. Osteoarthritis Cartilage. 1999;7:222-229.
39. Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. J Rheumatol. 1999;26:2664-2674.
40. Creamer P, Lethbridge-Ceiku M, Hochberg MC. Factors associated with functional impairment in symptomatic knee osteoarthritis. Rheumatology. 2000;39: 490-496.
41. Adams JG, McAlindon T, Dimasi M, Carey J, Eustace S. Contribution of meniscal extrusion and cartilage loss to joint space narrowing in osteoarthritis. Clin Radiol. 1999;54:502-506.
42. Mazzuca SA, Brandt KD. Plain radiography as an outcome measure in clinical trials involving patients with knee osteoarthritis. Rheum Dis Clin North Am. 1999; 25:467-480.
43. Creamer P, Lethbridge-Cejku M, Hochberg MC. Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures. J Rheumatol. 1999;26:1785-1792.
44. Noack W, Fischer M, Förster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:51-59.
45. Müller-Faßbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:61-69.
46. Rovati LC. The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: current data and perspectives [abstract]. Osteoarthritis Cartilage. 1997;5(suppl A):72.
47. Towheed TE, Anastassiades TP. Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. JAMA. 2000; 283:1483-1484.
48. Adams ME. Hype about glucosamine. Lancet. 1999;354:353-354.
49. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimitteiforschung. 2001;51:699-725.
50. Noyszewski EA, Wroblewski K, Dodge GR, et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum. 2001;44:1089-1095.
51. Bassleer C, Rovati LC, Franchimont P. Glucosamine sulfate stimulates proteoglycan production in human chondrocytes in vitro. Osteoarthritis Cartilage. 1998; 6:427-434.
52. Piperno M, Reboul P, Helio Le Graverand MP, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage. 2000;8:207-212.
53. Dodge GR, Hawkins DF, Jimenez SA. Modulation of aggrecan, MMP1, and MMP3 production by glucosamine sulfate in cultured human osteoarthritis articular chondrocytes [abstract]. Arthritis Rheum. 1999;42(suppl):S253.
54. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggreganase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J. 1998;335: 59-66.
55. Yaron I, Shirazi I, Judovich R, Yaron M. Glucosamine sulfate inhibits nitric oxide and stromelysin production in cartilage cultures and reverses IL-1 inhibition of osteoarthritic articular cartilage synthesis [abstract]. Ann Rheum Dis. 2001;60 (suppl):50.
56. Gouze JN, Bordji K, Gulberti S, et al. Interleukin-1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β-mediated effects in rat chondrocytes. Arthritis Rheum. 2001;44:351-360.
57. Setnikar I, Cereda R, Pacini MA, Revel L. Antireactive properties of glucosamine sulfate. Arzneimittelforschung. 1991;41:157-161.
58. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1 β-mediated activation of human chondrocytes. J Immunol. 2001;166:5155-5160.
59. Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, Tack CJ. Short-term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab. 2001;86:2099-2103.